Status:
COMPLETED
Safety and Effect of Mirapex(Pramipexole) Tablet Among Korean RLS
Lead Sponsor:
Boehringer Ingelheim
Conditions:
Restless Legs Syndrome
Eligibility:
All Genders
18+ years
Brief Summary
Safety and Effect of Mirapex(Pramipexole) tablet among Korean Restless Legs Syndrome Patients: An Open-Label, Postmarketing Surveillance Study
Detailed Description
Study Design:
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Moderate to severe Primary Restless Legs Syndrome
- Male or female patients aged at least 18 years
- Exclusion criteria:
- Any contraindications according to Basic Product Information (Company Core Data Sheet) or local Labelling; hypersensitivity to pramipexole or to any of the excipients.
- Ongoing treatment with Mirapex
- Pregnant and breastfeeding women
- Concomitant pharmacologic treatment with other dopaminergic drugs(including L-dopa)
- Secondary RLS
Exclusion
Key Trial Info
Start Date :
December 1 2007
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
651 Patients enrolled
Trial Details
Trial ID
NCT01170091
Start Date
December 1 2007
Last Update
April 11 2014
Active Locations (36)
Enter a location and click search to find clinical trials sorted by distance.
1
Boehringer Ingelheim Investigational Site 1
Busan, South Korea
2
Boehringer Ingelheim Investigational Site 2
Busan, South Korea
3
Boehringer Ingelheim Investigational Site 3
Busan, South Korea
4
Boehringer Ingelheim Investigational Site 32
Daegu, South Korea